Earnings ·
Ironwood raises full-year LINZESS sales guidance to $1.20-$1.25B, reports Q3 net income of $60M
IRWDIronwood Pharmaceuticals Inc
Ironwood Pharmaceuticals reported third-quarter GAAP net income of $60 million, or $0.36 per share, driven by a 4.9% increase in LINZESS prescription demand and improved commercial margins. The company raised its full-year 2026 financial guidance, increasing U.S. LINZESS net sales expectations to $1.20-$1.25 billion, total revenue to $485-$510 million, and adjusted EBITDA to greater than $350 million. Additionally, Chief Commercial Officer Tammi Gaskins is set to become CEO on January 1, 2027, succeeding retiring founder Tom McCourt. Ironwood Pharmaceuticals develops and commercializes therapies for gastrointestinal and rare diseases.